Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?

@article{Schmidt2002EcstasyCC,
  title={Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?},
  author={W. Schmidt and A. Mayerhofer and Anja Meyer and K. Kovar},
  journal={Neuroscience Letters},
  year={2002},
  volume={330},
  pages={251-254}
}
Parkinson's disease is due to a dopamine deficiency caused by the degeneration of midbrain dopamine neurons. Current therapies are aimed to substitute dopamine or to directly stimulate postsynaptic dopamine receptors. However, not all patients profit from current therapies to the same extent, even serious side effects such as dyskinesias are complicating the therapy. Therefore, there is still a need for better anti-parkinsonian drugs. Here we show that some compounds from the 'Ecstasy… Expand
Monoamine Reuptake Inhibitors in Parkinson's Disease
The serotonergic system in Parkinson's disease
MDMA ("Ecstasy") in Tiermodellen des Morbus Parkinson
MDMA modulates spontaneous firing of subthalamic nucleus neurons in vitro
Ecstasy: pharmacology and neurotoxicity.
  • J. Morton
  • Psychology, Medicine
  • Current opinion in pharmacology
  • 2005
MDMA and fenfluramine reduce L‐DOPA‐induced dyskinesia via indirect 5‐HT1A receptor stimulation
Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat
  • M. Wadenberg
  • Psychology, Medicine
  • Neuroscience & Biobehavioral Reviews
  • 1996
Serotonergic involvement in haloperidol-induced catalepsy.
Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons.
Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT1 receptor.
...
1
2
3
...